| Recruitment status | Completed |
| Unique ID issued by UMIN | UMIN000029484 |
| Receipt No. | R000033639 |
| Official scientific title of the study | A clinical study for evaluating of the effect of a complex food on postprandial serum triglyceride. |
| Date of disclosure of the study information | 2018/11/29 |
| Last modified on | 2019/03/05 (Ver. 2) |
| Basic information | ||
| Official scientific title of the study | A clinical study for evaluating of the effect of a complex food on postprandial serum triglyceride. | |
| Title of the study (Brief title) | Clinical study for the effect on TG | |
| Region |
|
|
| Condition | |||
| Condition | Healthy subjects with slightly higher fasting serum triglyceride level | ||
| Classification by specialty |
|
||
| Classification by malignancy | Others | ||
| Genomic information | NO | ||
| Objectives | |
| Narrative objectives1 | To evaluate the efficacy of the complex food on postprandial serum triglyceride(TG) and the safety. |
| Basic objectives2 | Safety,Efficacy |
| Basic objectives -Others | |
| Trial characteristics_1 | |
| Trial characteristics_2 | |
| Developmental phase | |
| Assessment | |
| Primary outcomes | The differences of serum TG level at sequential sampling point and AUC 0-6h between placebo and test food groups (The analysis of the actual measured values and the amount of changed values from baseline after the loading dietary fat) |
| Key secondary outcomes | The differences of serum level of remnant-like lipoprotein cholesterol at sequential sampling point and AUC 0-6h between placebo and test food groups (The analysis of the actual measured values and the amount of changed values from baseline after the loading dietary fat)
Assessment of safety (subjective and objective symptoms and blood chemistry). |
| Base | |
| Study type | Interventional |
| Study design | |
| Basic design | Cross-over |
| Randomization | Randomized |
| Randomization unit | Individual |
| Blinding | Double blind -all involved are blinded |
| Control | Placebo |
| Stratification | |
| Dynamic allocation | |
| Institution consideration | |
| Blocking | |
| Concealment | |
| Intervention | ||
| No. of arms | 2 | |
| Purpose of intervention | Prevention | |
| Type of intervention |
|
|
| Interventions/Control_1 | single ingestion of the placebo food - washout period (6 days or more) - single ingestion of the test food | |
| Interventions/Control_2 | single ingestion of the test food - washout period (6 days or more) - single ingestion of the placebo food | |
| Interventions/Control_3 | ||
| Interventions/Control_4 | ||
| Interventions/Control_5 | ||
| Interventions/Control_6 | ||
| Interventions/Control_7 | ||
| Interventions/Control_8 | ||
| Interventions/Control_9 | ||
| Interventions/Control_10 | ||
| Eligibility | ||||
| Age-lower limit |
|
|||
| Age-upper limit |
|
|||
| Gender | Male and Female | |||
| Key inclusion criteria | (1)Japanese males and females from 20 to 64 years of age when consented.
(2)Healthy subjects whose fasting serum TG levels is slightly high at pre-, 1st and 2nd screenings and whose time courses of serum TG after loading dietary food resemble each other at 1st and 2nd screening. (3)Subjects available at every designated visit. (4)Subjects who agree to participate in this study and can put signature and date to informed consent form by themselves prior to the study. |
|||
| Key exclusion criteria | (1) Subjects with hepatic, renal, cardiac or organ disorders or diabetes or other serious diseases.
(2) Subjects with a surgical history of digestive system (except appendicectom). (3) Subjects with a history of a previous drug or food allergy. (4) Subjects currently under treatment with chronic diseases. (5) Subjects who are pregnant or intend to become pregnant during the study or are lactating. (6) Subjects who are lactose intolerant or sensitive to fatty diet to show gastrointestinal symptoms. (7) Subjects who take excessive alcohol (equivalent to 540 mL of Japanese sake or more) for 5 days or more per week. (8) Subjects who take drugs or supplements which claim the suppressive absorption of sugar or lipid or reduction of triglyceride, etc. (9) Subjects who participate in other clinical trial. (10) Subjects who have a history of feeling ill or unwell during or after blood drawing. (11) Subjects who have donated over 200 mL of blood within the last one month prior to this study or expect to donate the same during the study. (12) Subjects with extremely irregular dietary life (shift worker, night- shift worker, etc.) (13) Subjects who had excessive eating and/or drinking during 3 days prior to each screening or prior to intervention period I or II. (14) Subjects who fasted repeatedly during 3 days prior to each screening or prior to intervention period I or II. (15) Subject who had excessive exercise than usual during 3 days prior to each screening or prior to intervention period I or II. (16) Subjects judged as unsuitable for this study by the investigator for other reasons. |
|||
| Target sample size | 40 | |||
| Research contact person | |
| Name of lead principal investigator | Jyoji Kurokawa |
| Organization | Iryouhoujinsyadan Shoureikan |
| Division name | Shinsapporo Seiryou Hospital |
| Address | 2-1-30, Atsubetsuhigashi 4-jo, Atsubetsu-ku Sapporo city, Hokkaido, 004-0004, Japan |
| TEL | 011-898-2151 |
| j.kurokawa@shoureikan.jp | |
| Public contact | |
| Name of contact person | Ryo Kanamori |
| Organization | Iryouhoujinsyadan Shoureikan |
| Division name | Shinsapporo Seiryou Hospital |
| Address | 22-1-30, Atsubetsuhigashi 4-jo, Atsubetsu-ku Sapporo city, Hokkaido, 004-0004, Japan |
| TEL | 011-898-2151 |
| Homepage URL | |
| kanamori@hpgr.jp | |
| Sponsor | |
| Institute | Iryouhoujinsyadan Shoureikan Shinsapporo Seiryou Hospital |
| Institute | |
| Department | |
| Funding Source | |
| Organization | FUJIFILM Corporation |
| Organization | |
| Division | |
| Category of Funding Organization | Profit organization |
| Nationality of Funding Organization | |
| Other related organizations | |
| Co-sponsor | |
| Name of secondary funder(s) | |
| Secondary IDs | |
| Secondary IDs | NO |
| Study ID_1 | |
| Org. issuing International ID_1 | |
| Study ID_2 | |
| Org. issuing International ID_2 | |
| IND to MHLW | |
| Institutions | |
| Institutions | 医療法人社団翔嶺館新札幌聖陵ホスピタル(北海道) |
| Other administrative information | |||||||
| Date of disclosure of the study information |
|
||||||
| Progress | |||||||
| Recruitment status | Completed | ||||||
| Date of protocol fixation |
|
||||||
| Anticipated trial start date |
|
||||||
| Last follow-up date | |||||||
| Date of closure to data entry | |||||||
| Date trial data considered complete | |||||||
| Date analysis concluded | |||||||
| Related information | |
| URL releasing protocol | |
| Publication of results | Published |
| URL releasing results | http://www.pieronline.jp/content/article/0386-3603/46120/1993 |
| Results | |
| Other related information | |
| Management information | |||||||
| Registered date |
|
||||||
| Last modified on |
|
||||||
| Link to view the page | |
| URL(English) | https://upload.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000033639 |